Combined endpoint and mortality at 14 days of all patients that were discharged within 24 h
| . | Combined endpoint of VTE, MB, or all-cause morality . | All-cause mortality . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Events (n) . | Patients (n) . | % . | (95% CI) . | RR . | (95% PI) . | Events (n) . | Patients (n) . | % . | (95% CI) . | RR . | (95% PI) . | |
| Overall | 15 | 2660 | 0.56 | (0.28–0.84) | 3 | 2664 | 0.11 | (0.0–0.24) | ||||
| Age | ||||||||||||
| 18–40* | 3 | 580 | 0.52 | (0.0–1.1) | 0 | 582 | 0.00 | (0.0–0) | ||||
| 41–60 | 8 | 1086 | 0.74 | (0.23–1.3) | 1.10 | (0.66–1.8) | 2 | 1086 | 0.18 | (0.0–0.44) | 1.28 | (0.9–1.82) |
| 61–80 | 4 | 894 | 0.45 | (0.01–0.8) | 0.96 | (0.48–1.4) | 1 | 896 | 0.11 | (0.0–0.33) | 1.14 | (0.86–1.5) |
| >81 | 0 | 99 | 0.00 | (0.0–0) | 0.77 | (0.52–1.2) | 0 | 99 | 0.00 | (0.0–0) | NA | NA |
| Sex | ||||||||||||
| Female | 6 | 1264 | 0.47 | (0.09–0.85) | 1.1 | (0.48–2.4) | 2 | 1266 | 0.16 | (0.0–0.38) | 1.3 | (0.65–2.5) |
| Male* | 9 | 1396 | 0.64 | (0.22–1.1) | 1 | 1398 | 0.07 | (0.0–0.21) | ||||
| Symptoms | ||||||||||||
| Incidental | 0 | 15 | 0.00 | (0.0–0) | 1.0 | (0.0–1005) | 0 | 15 | 0.00 | (0.0–0) | 1.0 | (0.0–1005) |
| Symptomatic* | 10 | 1641 | 0.61 | (0.23–0.99) | 3 | 1641 | 0.18 | (0.0–0.39) | ||||
| Treatment | ||||||||||||
| LMWH or VKA | 7 | 1012 | 0.69 | (0.18–1.2) | 1.3 | (0.78–2.3) | 3 | 1014 | 0.30 | (0.0–0.63) | 3.1 | (0.17–56) |
| DOAC* | 8 | 1532 | 0.52 | (0.16–0.88) | 0 | 1534 | 0.00 | (0.0–0) | ||||
| Cancera | ||||||||||||
| Yes | 1 | 217 | 0.46 | (0.0–1.4) | 1.7 | (0.7–3.9) | 1 | 219 | 0.46 | (0.0–1.4) | 2.9 | (0.8–10) |
| No* | 14 | 2443 | 0.57 | (0.27–0.87) | 2 | 2445 | 0.08 | (0.0–0.19) | ||||
| Previous VTE | ||||||||||||
| Yes | 7 | 830 | 0.81 | (0.2–1.4) | 1.3 | (0.55–3.3) | 1 | 831 | 0.12 | (0.0–0.36) | 1.3 | (0.49–3.4) |
| No* | 8 | 1714 | 0.48 | (0.15–0.81) | 2 | 1717 | 0.12 | (0.0–0.28) | ||||
| Decreased kidney functionb | ||||||||||||
| Yes | 1 | 203 | 0.25 | (0.0–0.94) | 0.47 | (0.22–1.0) | 0 | 203 | 0.00 | (0.0–0) | 0.78 | (0.58–1.1) |
| No* | 14 | 2457 | 0.59 | (0.29–0.89) | 3 | 2461 | 0.12 | (0.0–0.26) | ||||
| Pre-existing cardiopulmonary diseasec | ||||||||||||
| Yes | 6 | 479 | 1.30 | (0.29–2.3) | 3.5 | (1.5–7.9) | 1 | 480 | 0.28 | (0.0–0.75) | 2. 70g | (0.68–11) |
| No* | 9 | 2181 | 0.40 | (0.13–0.67) | 2 | 2184 | 0.08 | (0.0–0.2) | ||||
| Abnormal troponind | ||||||||||||
| Yes | 3 | 249 | 1.23 | (0.0–2.6) | 2.5 | (1.3–4.9) | 0 | 249 | 0.14 | (0.0–0.6) | 0.86 | (0.56–1.3) |
| No* | 8 | 1946 | 0.41 | (0.13–0.69) | 2 | 1950 | 0.08 | (0.0–0.21) | ||||
| Abnormal (NT-pro)BNPe | ||||||||||||
| Yes | 3 | 210 | 1.60 | (0.0–3.3) | 3.9 | (1.6–9.8) | 0 | 210 | 0.10 | (0.0–0.53) | 0.93 | (0.75–1.1) |
| No* | 8 | 2154 | 0.35 | (0.1–0.6) | 2 | 2158 | 0.08 | (0.0–0.2) | ||||
| Signs of RV overloadf | ||||||||||||
| Yes | 5 | 326 | 1.69 | (0.29–3.1) | 2.7 | (0.62–11) | 0 | 327 | 0.15 | (0.0–0.57) | 0.49 | (0.1–2.4) |
| No* | 3 | 910 | 0.28 | (0.0–0.62) | 2 | 913 | 0.17 | (0.0–0.43) | ||||
| . | Combined endpoint of VTE, MB, or all-cause morality . | All-cause mortality . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Events (n) . | Patients (n) . | % . | (95% CI) . | RR . | (95% PI) . | Events (n) . | Patients (n) . | % . | (95% CI) . | RR . | (95% PI) . | |
| Overall | 15 | 2660 | 0.56 | (0.28–0.84) | 3 | 2664 | 0.11 | (0.0–0.24) | ||||
| Age | ||||||||||||
| 18–40* | 3 | 580 | 0.52 | (0.0–1.1) | 0 | 582 | 0.00 | (0.0–0) | ||||
| 41–60 | 8 | 1086 | 0.74 | (0.23–1.3) | 1.10 | (0.66–1.8) | 2 | 1086 | 0.18 | (0.0–0.44) | 1.28 | (0.9–1.82) |
| 61–80 | 4 | 894 | 0.45 | (0.01–0.8) | 0.96 | (0.48–1.4) | 1 | 896 | 0.11 | (0.0–0.33) | 1.14 | (0.86–1.5) |
| >81 | 0 | 99 | 0.00 | (0.0–0) | 0.77 | (0.52–1.2) | 0 | 99 | 0.00 | (0.0–0) | NA | NA |
| Sex | ||||||||||||
| Female | 6 | 1264 | 0.47 | (0.09–0.85) | 1.1 | (0.48–2.4) | 2 | 1266 | 0.16 | (0.0–0.38) | 1.3 | (0.65–2.5) |
| Male* | 9 | 1396 | 0.64 | (0.22–1.1) | 1 | 1398 | 0.07 | (0.0–0.21) | ||||
| Symptoms | ||||||||||||
| Incidental | 0 | 15 | 0.00 | (0.0–0) | 1.0 | (0.0–1005) | 0 | 15 | 0.00 | (0.0–0) | 1.0 | (0.0–1005) |
| Symptomatic* | 10 | 1641 | 0.61 | (0.23–0.99) | 3 | 1641 | 0.18 | (0.0–0.39) | ||||
| Treatment | ||||||||||||
| LMWH or VKA | 7 | 1012 | 0.69 | (0.18–1.2) | 1.3 | (0.78–2.3) | 3 | 1014 | 0.30 | (0.0–0.63) | 3.1 | (0.17–56) |
| DOAC* | 8 | 1532 | 0.52 | (0.16–0.88) | 0 | 1534 | 0.00 | (0.0–0) | ||||
| Cancera | ||||||||||||
| Yes | 1 | 217 | 0.46 | (0.0–1.4) | 1.7 | (0.7–3.9) | 1 | 219 | 0.46 | (0.0–1.4) | 2.9 | (0.8–10) |
| No* | 14 | 2443 | 0.57 | (0.27–0.87) | 2 | 2445 | 0.08 | (0.0–0.19) | ||||
| Previous VTE | ||||||||||||
| Yes | 7 | 830 | 0.81 | (0.2–1.4) | 1.3 | (0.55–3.3) | 1 | 831 | 0.12 | (0.0–0.36) | 1.3 | (0.49–3.4) |
| No* | 8 | 1714 | 0.48 | (0.15–0.81) | 2 | 1717 | 0.12 | (0.0–0.28) | ||||
| Decreased kidney functionb | ||||||||||||
| Yes | 1 | 203 | 0.25 | (0.0–0.94) | 0.47 | (0.22–1.0) | 0 | 203 | 0.00 | (0.0–0) | 0.78 | (0.58–1.1) |
| No* | 14 | 2457 | 0.59 | (0.29–0.89) | 3 | 2461 | 0.12 | (0.0–0.26) | ||||
| Pre-existing cardiopulmonary diseasec | ||||||||||||
| Yes | 6 | 479 | 1.30 | (0.29–2.3) | 3.5 | (1.5–7.9) | 1 | 480 | 0.28 | (0.0–0.75) | 2. 70g | (0.68–11) |
| No* | 9 | 2181 | 0.40 | (0.13–0.67) | 2 | 2184 | 0.08 | (0.0–0.2) | ||||
| Abnormal troponind | ||||||||||||
| Yes | 3 | 249 | 1.23 | (0.0–2.6) | 2.5 | (1.3–4.9) | 0 | 249 | 0.14 | (0.0–0.6) | 0.86 | (0.56–1.3) |
| No* | 8 | 1946 | 0.41 | (0.13–0.69) | 2 | 1950 | 0.08 | (0.0–0.21) | ||||
| Abnormal (NT-pro)BNPe | ||||||||||||
| Yes | 3 | 210 | 1.60 | (0.0–3.3) | 3.9 | (1.6–9.8) | 0 | 210 | 0.10 | (0.0–0.53) | 0.93 | (0.75–1.1) |
| No* | 8 | 2154 | 0.35 | (0.1–0.6) | 2 | 2158 | 0.08 | (0.0–0.2) | ||||
| Signs of RV overloadf | ||||||||||||
| Yes | 5 | 326 | 1.69 | (0.29–3.1) | 2.7 | (0.62–11) | 0 | 327 | 0.15 | (0.0–0.57) | 0.49 | (0.1–2.4) |
| No* | 3 | 910 | 0.28 | (0.0–0.62) | 2 | 913 | 0.17 | (0.0–0.43) | ||||
This table presents the 14-day incidence of the combined endpoint of VTE, MB, or all-cause mortality and the 14-day incidence of all-cause mortality. Relative risk presents the ratio of the risk for an event for the exposure group to the risk for the non-exposure/reference group. Non-exposure/reference group is marked with an asterisk.
CI, confidence interval; DOAC, direct oral anticoagulant; LMWH, low-molecular-weight heparin; MB, major bleeding; NA, not applicable; PI, prediction interval; RR, relative risk; RV, right ventricle; TTE, transthoracic echocardiography; VKA, vitamin K antagonist; VTE, venous thromboembolism.
a(i) Current diagnosis of cancer, (ii) receiving treatment for cancer, or (iii) not receiving treatment for cancer and not in complete response.
bEstimated glomerular filtration rate < 60 mL/min.
cPre-existing pulmonary disease was defined as a history of chronic obstructive pulmonary disease, asthma, or lung fibrosis; a pre-existing cardiovascular disease was defined as any of coronary artery disease, heart failure, congenital heart disease, cardiomyopathy, or rheumatic heart disease.
dAbnormal troponin was defined as a troponin level > 99th percentile according to local technique.
e(NT-pro)BNP > 500 ng/L or BNP level > 100 ng/L.
fRight ventricle/left ventricle ratio > 0.9 on computed tomography pulmonary angiogram or echocardiogram.
gI2 were all 0% for all analysis, except for I2 = 0.68%.
Combined endpoint and mortality at 14 days of all patients that were discharged within 24 h
| . | Combined endpoint of VTE, MB, or all-cause morality . | All-cause mortality . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Events (n) . | Patients (n) . | % . | (95% CI) . | RR . | (95% PI) . | Events (n) . | Patients (n) . | % . | (95% CI) . | RR . | (95% PI) . | |
| Overall | 15 | 2660 | 0.56 | (0.28–0.84) | 3 | 2664 | 0.11 | (0.0–0.24) | ||||
| Age | ||||||||||||
| 18–40* | 3 | 580 | 0.52 | (0.0–1.1) | 0 | 582 | 0.00 | (0.0–0) | ||||
| 41–60 | 8 | 1086 | 0.74 | (0.23–1.3) | 1.10 | (0.66–1.8) | 2 | 1086 | 0.18 | (0.0–0.44) | 1.28 | (0.9–1.82) |
| 61–80 | 4 | 894 | 0.45 | (0.01–0.8) | 0.96 | (0.48–1.4) | 1 | 896 | 0.11 | (0.0–0.33) | 1.14 | (0.86–1.5) |
| >81 | 0 | 99 | 0.00 | (0.0–0) | 0.77 | (0.52–1.2) | 0 | 99 | 0.00 | (0.0–0) | NA | NA |
| Sex | ||||||||||||
| Female | 6 | 1264 | 0.47 | (0.09–0.85) | 1.1 | (0.48–2.4) | 2 | 1266 | 0.16 | (0.0–0.38) | 1.3 | (0.65–2.5) |
| Male* | 9 | 1396 | 0.64 | (0.22–1.1) | 1 | 1398 | 0.07 | (0.0–0.21) | ||||
| Symptoms | ||||||||||||
| Incidental | 0 | 15 | 0.00 | (0.0–0) | 1.0 | (0.0–1005) | 0 | 15 | 0.00 | (0.0–0) | 1.0 | (0.0–1005) |
| Symptomatic* | 10 | 1641 | 0.61 | (0.23–0.99) | 3 | 1641 | 0.18 | (0.0–0.39) | ||||
| Treatment | ||||||||||||
| LMWH or VKA | 7 | 1012 | 0.69 | (0.18–1.2) | 1.3 | (0.78–2.3) | 3 | 1014 | 0.30 | (0.0–0.63) | 3.1 | (0.17–56) |
| DOAC* | 8 | 1532 | 0.52 | (0.16–0.88) | 0 | 1534 | 0.00 | (0.0–0) | ||||
| Cancera | ||||||||||||
| Yes | 1 | 217 | 0.46 | (0.0–1.4) | 1.7 | (0.7–3.9) | 1 | 219 | 0.46 | (0.0–1.4) | 2.9 | (0.8–10) |
| No* | 14 | 2443 | 0.57 | (0.27–0.87) | 2 | 2445 | 0.08 | (0.0–0.19) | ||||
| Previous VTE | ||||||||||||
| Yes | 7 | 830 | 0.81 | (0.2–1.4) | 1.3 | (0.55–3.3) | 1 | 831 | 0.12 | (0.0–0.36) | 1.3 | (0.49–3.4) |
| No* | 8 | 1714 | 0.48 | (0.15–0.81) | 2 | 1717 | 0.12 | (0.0–0.28) | ||||
| Decreased kidney functionb | ||||||||||||
| Yes | 1 | 203 | 0.25 | (0.0–0.94) | 0.47 | (0.22–1.0) | 0 | 203 | 0.00 | (0.0–0) | 0.78 | (0.58–1.1) |
| No* | 14 | 2457 | 0.59 | (0.29–0.89) | 3 | 2461 | 0.12 | (0.0–0.26) | ||||
| Pre-existing cardiopulmonary diseasec | ||||||||||||
| Yes | 6 | 479 | 1.30 | (0.29–2.3) | 3.5 | (1.5–7.9) | 1 | 480 | 0.28 | (0.0–0.75) | 2. 70g | (0.68–11) |
| No* | 9 | 2181 | 0.40 | (0.13–0.67) | 2 | 2184 | 0.08 | (0.0–0.2) | ||||
| Abnormal troponind | ||||||||||||
| Yes | 3 | 249 | 1.23 | (0.0–2.6) | 2.5 | (1.3–4.9) | 0 | 249 | 0.14 | (0.0–0.6) | 0.86 | (0.56–1.3) |
| No* | 8 | 1946 | 0.41 | (0.13–0.69) | 2 | 1950 | 0.08 | (0.0–0.21) | ||||
| Abnormal (NT-pro)BNPe | ||||||||||||
| Yes | 3 | 210 | 1.60 | (0.0–3.3) | 3.9 | (1.6–9.8) | 0 | 210 | 0.10 | (0.0–0.53) | 0.93 | (0.75–1.1) |
| No* | 8 | 2154 | 0.35 | (0.1–0.6) | 2 | 2158 | 0.08 | (0.0–0.2) | ||||
| Signs of RV overloadf | ||||||||||||
| Yes | 5 | 326 | 1.69 | (0.29–3.1) | 2.7 | (0.62–11) | 0 | 327 | 0.15 | (0.0–0.57) | 0.49 | (0.1–2.4) |
| No* | 3 | 910 | 0.28 | (0.0–0.62) | 2 | 913 | 0.17 | (0.0–0.43) | ||||
| . | Combined endpoint of VTE, MB, or all-cause morality . | All-cause mortality . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Events (n) . | Patients (n) . | % . | (95% CI) . | RR . | (95% PI) . | Events (n) . | Patients (n) . | % . | (95% CI) . | RR . | (95% PI) . | |
| Overall | 15 | 2660 | 0.56 | (0.28–0.84) | 3 | 2664 | 0.11 | (0.0–0.24) | ||||
| Age | ||||||||||||
| 18–40* | 3 | 580 | 0.52 | (0.0–1.1) | 0 | 582 | 0.00 | (0.0–0) | ||||
| 41–60 | 8 | 1086 | 0.74 | (0.23–1.3) | 1.10 | (0.66–1.8) | 2 | 1086 | 0.18 | (0.0–0.44) | 1.28 | (0.9–1.82) |
| 61–80 | 4 | 894 | 0.45 | (0.01–0.8) | 0.96 | (0.48–1.4) | 1 | 896 | 0.11 | (0.0–0.33) | 1.14 | (0.86–1.5) |
| >81 | 0 | 99 | 0.00 | (0.0–0) | 0.77 | (0.52–1.2) | 0 | 99 | 0.00 | (0.0–0) | NA | NA |
| Sex | ||||||||||||
| Female | 6 | 1264 | 0.47 | (0.09–0.85) | 1.1 | (0.48–2.4) | 2 | 1266 | 0.16 | (0.0–0.38) | 1.3 | (0.65–2.5) |
| Male* | 9 | 1396 | 0.64 | (0.22–1.1) | 1 | 1398 | 0.07 | (0.0–0.21) | ||||
| Symptoms | ||||||||||||
| Incidental | 0 | 15 | 0.00 | (0.0–0) | 1.0 | (0.0–1005) | 0 | 15 | 0.00 | (0.0–0) | 1.0 | (0.0–1005) |
| Symptomatic* | 10 | 1641 | 0.61 | (0.23–0.99) | 3 | 1641 | 0.18 | (0.0–0.39) | ||||
| Treatment | ||||||||||||
| LMWH or VKA | 7 | 1012 | 0.69 | (0.18–1.2) | 1.3 | (0.78–2.3) | 3 | 1014 | 0.30 | (0.0–0.63) | 3.1 | (0.17–56) |
| DOAC* | 8 | 1532 | 0.52 | (0.16–0.88) | 0 | 1534 | 0.00 | (0.0–0) | ||||
| Cancera | ||||||||||||
| Yes | 1 | 217 | 0.46 | (0.0–1.4) | 1.7 | (0.7–3.9) | 1 | 219 | 0.46 | (0.0–1.4) | 2.9 | (0.8–10) |
| No* | 14 | 2443 | 0.57 | (0.27–0.87) | 2 | 2445 | 0.08 | (0.0–0.19) | ||||
| Previous VTE | ||||||||||||
| Yes | 7 | 830 | 0.81 | (0.2–1.4) | 1.3 | (0.55–3.3) | 1 | 831 | 0.12 | (0.0–0.36) | 1.3 | (0.49–3.4) |
| No* | 8 | 1714 | 0.48 | (0.15–0.81) | 2 | 1717 | 0.12 | (0.0–0.28) | ||||
| Decreased kidney functionb | ||||||||||||
| Yes | 1 | 203 | 0.25 | (0.0–0.94) | 0.47 | (0.22–1.0) | 0 | 203 | 0.00 | (0.0–0) | 0.78 | (0.58–1.1) |
| No* | 14 | 2457 | 0.59 | (0.29–0.89) | 3 | 2461 | 0.12 | (0.0–0.26) | ||||
| Pre-existing cardiopulmonary diseasec | ||||||||||||
| Yes | 6 | 479 | 1.30 | (0.29–2.3) | 3.5 | (1.5–7.9) | 1 | 480 | 0.28 | (0.0–0.75) | 2. 70g | (0.68–11) |
| No* | 9 | 2181 | 0.40 | (0.13–0.67) | 2 | 2184 | 0.08 | (0.0–0.2) | ||||
| Abnormal troponind | ||||||||||||
| Yes | 3 | 249 | 1.23 | (0.0–2.6) | 2.5 | (1.3–4.9) | 0 | 249 | 0.14 | (0.0–0.6) | 0.86 | (0.56–1.3) |
| No* | 8 | 1946 | 0.41 | (0.13–0.69) | 2 | 1950 | 0.08 | (0.0–0.21) | ||||
| Abnormal (NT-pro)BNPe | ||||||||||||
| Yes | 3 | 210 | 1.60 | (0.0–3.3) | 3.9 | (1.6–9.8) | 0 | 210 | 0.10 | (0.0–0.53) | 0.93 | (0.75–1.1) |
| No* | 8 | 2154 | 0.35 | (0.1–0.6) | 2 | 2158 | 0.08 | (0.0–0.2) | ||||
| Signs of RV overloadf | ||||||||||||
| Yes | 5 | 326 | 1.69 | (0.29–3.1) | 2.7 | (0.62–11) | 0 | 327 | 0.15 | (0.0–0.57) | 0.49 | (0.1–2.4) |
| No* | 3 | 910 | 0.28 | (0.0–0.62) | 2 | 913 | 0.17 | (0.0–0.43) | ||||
This table presents the 14-day incidence of the combined endpoint of VTE, MB, or all-cause mortality and the 14-day incidence of all-cause mortality. Relative risk presents the ratio of the risk for an event for the exposure group to the risk for the non-exposure/reference group. Non-exposure/reference group is marked with an asterisk.
CI, confidence interval; DOAC, direct oral anticoagulant; LMWH, low-molecular-weight heparin; MB, major bleeding; NA, not applicable; PI, prediction interval; RR, relative risk; RV, right ventricle; TTE, transthoracic echocardiography; VKA, vitamin K antagonist; VTE, venous thromboembolism.
a(i) Current diagnosis of cancer, (ii) receiving treatment for cancer, or (iii) not receiving treatment for cancer and not in complete response.
bEstimated glomerular filtration rate < 60 mL/min.
cPre-existing pulmonary disease was defined as a history of chronic obstructive pulmonary disease, asthma, or lung fibrosis; a pre-existing cardiovascular disease was defined as any of coronary artery disease, heart failure, congenital heart disease, cardiomyopathy, or rheumatic heart disease.
dAbnormal troponin was defined as a troponin level > 99th percentile according to local technique.
e(NT-pro)BNP > 500 ng/L or BNP level > 100 ng/L.
fRight ventricle/left ventricle ratio > 0.9 on computed tomography pulmonary angiogram or echocardiogram.
gI2 were all 0% for all analysis, except for I2 = 0.68%.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
